223 related articles for article (PubMed ID: 29332125)
1. ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells.
Kaochar S; Dong J; Torres M; Rajapakshe K; Nikolos F; Davis CM; Ehli EA; Coarfa C; Mitsiades N; Poulaki V
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):132-143. PubMed ID: 29332125
[TBL] [Abstract][Full Text] [Related]
2. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.
Arensman MD; Telesca D; Lay AR; Kershaw KM; Wu N; Donahue TR; Dawson DW
Mol Cancer Ther; 2014 Oct; 13(10):2303-14. PubMed ID: 25082960
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
4. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation.
Samadi AK; Cohen SM; Mukerji R; Chaguturu V; Zhang X; Timmermann BN; Cohen MS; Person EA
Tumour Biol; 2012 Aug; 33(4):1179-89. PubMed ID: 22477711
[TBL] [Abstract][Full Text] [Related]
5. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
Zhou J; Jin B; Jin Y; Liu Y; Pan J
Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
[TBL] [Abstract][Full Text] [Related]
6. Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma.
Jin Y; Zhang P; Wang Y; Jin B; Zhou J; Zhang J; Pan J
Clin Cancer Res; 2018 Aug; 24(15):3741-3754. PubMed ID: 29233905
[No Abstract] [Full Text] [Related]
7. Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner.
Grigson ER; Ozerova M; Pisklakova A; Liu H; Sullivan DM; Nefedova Y
PLoS One; 2015; 10(1):e0117693. PubMed ID: 25635944
[TBL] [Abstract][Full Text] [Related]
8. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
9. The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
Wiese M; Walther N; Diederichs C; Schill F; Monecke S; Salinas G; Sturm D; Pfister SM; Dressel R; Johnsen SA; Kramm CM
Oncotarget; 2017 Apr; 8(16):27300-27313. PubMed ID: 28460484
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
11. Monensin synergizes with chemotherapy in uveal melanoma through suppressing RhoA.
Zeng C; Long M; Lu Y
Immunopharmacol Immunotoxicol; 2023 Feb; 45(1):35-42. PubMed ID: 36043455
[TBL] [Abstract][Full Text] [Related]
12. Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma.
Bustamante P; Miyamoto D; Goyeneche A; de Alba Graue PG; Jin E; Tsering T; Dias AB; Burnier MN; Burnier JV
Cancer Med; 2019 Dec; 8(17):7265-7277. PubMed ID: 31588689
[TBL] [Abstract][Full Text] [Related]
13. The role of RASSF1A in uveal melanoma.
Dratviman-Storobinsky O; Cohen Y; Frenkel S; Merhavi-Shoham E; El SD; Binkovsky N; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2012 Oct; 53(6):2611-9. PubMed ID: 22447862
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model.
Liu S; Song W; Liu F; Zhang J; Zhu S
Exp Eye Res; 2018 Jul; 172():144-151. PubMed ID: 29660328
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.
Zhang J; Liu S; Ye Q; Pan J
Mol Cancer; 2019 Sep; 18(1):140. PubMed ID: 31526394
[TBL] [Abstract][Full Text] [Related]
16. Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.
Weidmann C; Bérubé J; Piquet L; de la Fouchardière A; Landreville S
Clin Exp Metastasis; 2018 Mar; 35(3):123-134. PubMed ID: 29696577
[TBL] [Abstract][Full Text] [Related]
17. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
18. Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways.
Xie X; Xie S; Xie C; Fang Y; Li Z; Wang R; Jiang W
J Cell Mol Med; 2019 Nov; 23(11):7545-7553. PubMed ID: 31508890
[TBL] [Abstract][Full Text] [Related]
19. The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.
Shu W; Zhu X; Wang K; Cherepanoff S; Conway RM; Madigan MC; Zhu H; Zhu L; Murray M; Zhou F
Cell Oncol (Dordr); 2022 Aug; 45(4):601-619. PubMed ID: 35781872
[TBL] [Abstract][Full Text] [Related]
20. Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF‑κB pathway.
Zhang B; Zhang J; Pan J
Int J Oncol; 2017 Sep; 51(3):887-898. PubMed ID: 28766683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
